Very important issue: Delhi High Court on plea against rollout of HPV vaccines without adequate study

The Delhi High Court has issued notice to the Central government and the Indian Council of Medical Research (ICMR) on a plea challenging the nationwide rollout of the Human Papillomavirus (HPV) vaccine, Gardasil, without adequate study. The court will hear the matter on July 29, with Additional Solicitor General Chetan Sharma assisting in the case.

The Delhi High Court has issued notice to the Central government and the Indian Council of Medical Research (ICMR) on a plea challenging the nationwide rollout of the Human Papillomavirus (HPV) vaccine, Gardasil, without adequate study. This development is significant as it highlights concerns over the safety and efficacy of the vaccine, which is being administered to adolescent girls under the Universal Immunisation Programme (UIP). The court's decision to hear the matter on July 29 underscores the importance of ensuring that any vaccination programme is thoroughly studied and vetted before its rollout.

The HPV vaccine, Gardasil, has been introduced as part of India's Universal Immunisation Programme (UIP) to protect adolescent girls against cervical, anal, throat, and penile cancers. However, the introduction of the vaccine without adequate study has raised concerns over its safety and efficacy. The Delhi High Court's decision to issue notice to the Central government and ICMR is a response to these concerns.

The court's decision to hear the matter on July 29 suggests that it will carefully examine the issues surrounding the rollout of the HPV vaccine. The court's remarks, which emphasized the importance of being cautious in ensuring the safety of girl children, indicate that it will not take a lenient view of the government's actions. The involvement of Additional Solicitor General Chetan Sharma as an assisting officer highlights the gravity of the matter and the need for careful consideration.

The Delhi High Court's decision to issue notice to the Central government and ICMR on the plea challenging the rollout of the HPV vaccine is a significant development. The court's commitment to ensuring the safety and efficacy of vaccination programmes is commendable, and its decision to hear the matter on July 29 underscores the importance of thorough study and vetting before any programme is rolled out.